Develops anti-IL-1 monoclonal antibodies for immune-mediated inflammatory diseases.
Dec 2025Revenue $59.0K/yrExpenses $73.0M/yr
No trendCash runway ≈ 5.9 years from Jun 2026
Figures by year
When will Avalo Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $59.0K and expenses $73.0M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $59.0K | $73.0M | −$72.9M |
| Dec 2024 | $441K | $69.0M | −$68.5M |
| Dec 2023 | $1.92M | $29.3M | −$27.4M |
| Dec 2022 | $18.1M | $55.5M | −$37.4M |
| Dec 2021 | $5.40M | $87.5M | −$82.1M |
| Dec 2020 | $6.70M | $79.5M | −$72.8M |
| Dec 2019 | $6.75M | $22.9M | −$16.1M |
| Dec 2018 | $7.03M | $42.4M | −$35.4M |
| Dec 2017 | $27.8M | $13.9M | $13.9M |
| Dec 2016 | $1.15M | $17.2M | −$16.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.